PharmaVentures Strengthens its M&A and Fundraising Capabilities with the Appointment of a New Managing Director, Mark Andrews

OXFORD, England, Nov. 26, 2019 /PRNewswire/ -- PharmaVentures is pleased to announce the appointment of Mark Andrews as a Managing Director. Prior to joining PharmaVentures, Mark was a core member of the Corporate Finance M&A Life Science sector team at BDO in London, where he worked with clients especially in the outsourced pharma services and medical devices sectors.

Previously Mark was at Inventages, the Corporate VC of Nestle, based in both Switzerland & London. During this time, he managed numerous life science investments and took positions on the boards of, or took up board observer rights for, the vast majority of portfolio companies. Prior to that he was at DEWB Venture Capital in Jena, Germany. His experience spans across the investment cycle, from sourcing through investment negotiation to hands-on portfolio management, driving towards exit negotiation.

Fintan Walton, PhD, Chief Executive of PharmaVentures, said: "We are delighted to welcome Mark to PharmaVentures. He has an impressive track record in life science investments and dealmaking. His wealth of experience will add significant value to our clients in their M&A and fundraising activities."

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures Capital Limited is a wholly owned subsidiary of PharmaVentures Limited. All regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Limited undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5. Securities offered in the United States through Crito Capital LLC, member FINRA, SIPC and MSRB.

Find out more www.pharmaventures.com

Services include:

• Corporate Advisory (M&A, divestments, Partnering - licensing in and out)
• Private Placement Fundraising
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fundraising & expert testimonies)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)

PharmaVentures is based in Oxford, UK, employs over 20 professionals and has associates across Europe, North America, Latin America and Asia-Pacific.

For further information, contact:
Dr Fintan Walton
Chief Executive
PharmaVentures Ltd
+44-1865-332-700
enquiries@pharmaventures.com